Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
Background Elderly patients are at high risk of ischaemic and bleeding events. Platelet function monitoring offers the possibility to individualise antiplatelet therapy to improve the therapeutic risk-benefit ratio. We aimed to assess the effect of platelet function monitoring with treatment adjustment in elderly patients stented for an acute coronary syndrome.Methods We did this multicentre, open-label, blinded-endpoint, randomised controlled superiority study at 35 centres in France. Patients aged 75 years or older who had undergone coronary stenting for acute coronary syndrome were randomly assigned (1:1), via a central interactive voice-response system based on a computer-generated permuted-block randomisation schedule with randomly selected block sizes, to receive oral prasugrel 5 mg daily with dose or drug adjustment in case of inadequate response (monitoring group) or oral prasugrel 5 mg daily with no monitoring or treatment adjustment (conventional group). Randomisation was stratified by centre. Platelet function testing was done 14 days after randomisation and repeated 14 days after treatment adjustment in patients in the monitoring group. Study investigators and patients were not masked to treatment allocation, but allocation was concealed from an independent clinical events committee responsible for endpoint adjudication. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, stent thrombosis, urgent revascularisation, and Bleeding Academic Research Consortium-defined bleeding complications (types 2, 3, or 5) at 12 months' follow-up. We did analysis by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01538446.Findings Between March 27, 2012, and May 19, 2015, we randomly assigned 877 patients to the monitoring group (n=442) or the conventional group (n=435). The primary endpoint occurred in 120 (28%) patients in the monitoring group compared with 123 (28%) patients in the conventional group (hazard ratio [HR], 1·003, 95% CI 0·78-1·29; p=0·98). Rates of bleeding events did not differ significantly between groups.Interpretation Platelet function monitoring with treatment adjustment did not improve the clinical outcome of elderly patients treated with coronary stenting for an acute coronary syndrome. Platelet function testing is still being used in many centres and international guidelines still recommend platelet function testing in high-risk situations. Our study does not support this practice or these recommendations.Funding Eli Lilly and Company, Daiichi Sankyo, Stentys, Accriva Diagnostics, Medtronic, and Fondation Coeur et Recherche.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, patients with T2DM have a reduced generation of the active metabolite of clopidogrel compared with patients without diabetes (Supplementary data online, Section 2.7).323,324”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [323]
In the citing paper
“In addition, patients with diabetes form less of the clopidogrel active metabolite resulting in less platelet inhibition”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [323]
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citationWriting Committee Members, Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823ba622 · Cited by 3,289
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.007 · Cited by 2,164
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Price, M. J. (2011) · JAMA · doi:10.1001/jama.2011.290 · Cited by 1,308
Alexander, K. P., Newby, L. K., Cannon, C. P., Armstrong, P. W., Gibler, W. B., Rich, M. W., Van de Werf, F., White, H. D., Weaver, W. D., Naylor, M. D., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.182615 · Cited by 914
Tantry, U. S., Bonello, L., Aradi, D., Price, M. J., Jeong, Y.-H., Angiolillo, D. J., Stone, G. W., Curzen, N., Geisler, T., ten Berg, J., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.101 · Cited by 910
Bedside monitoring to adjust antiplatelet therapy for coronary stenting
Collet, J.-P., Cuisset, T., Rangé, G., Cayla, G., Elhadad, S., Pouillot, C., Henry, P., Motreff, P., Carrié, D., Boueri, Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209979 · Cited by 887
Self-citationStone, G. W., Witzenbichler, B., Weisz, G., Rinaldi, M. J., Neumann, F.-J., Metzger, D. C., Henry, T. D., Cox, D. A., Duffy, P. L., Mazzaferri, E., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61170-8 · Cited by 857
Research works printed but not linked: 1
- Kolh, 2014, ESC/EACTS myocardial revascularization guidelines 2014, Eur Heart J, 35, 3235
Cited by
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx419 · Cited by 2,987
Self-citation2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI
Claassens, D. M. F., Vos, G. J. A., Bergmeijer, T. O., Hermanides, R. S., van ’t Hof, A. W. J., van der Harst, P., Barbato, E., Morisco, C., Tjon Joe Gin, R. M., Asselbergs, F. W., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907096 · Cited by 654
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
Metadata
- Authors
- Cayla, G., Cuisset, T., Silvain, J., Leclercq, F., Manzo-Silberman, S., Saint-Etienne, C., Delarche, N., Bellemain-Appaix, A., Range, G., El Mahmoud, R., Carrié, D., Belle, L., Souteyrand, G., Aubry, P., Sabouret, P., du Fretay, X. H., Beygui, F., Bonnet, J.-L., Lattuca, B., Pouillot, C., Varenne, O., Boueri, Z., Van Belle, E., Henry, P., Motreff, P., Elhadad, S., Salem, J.-E., Abtan, J., Rousseau, H., Collet, J.-P., Vicaut, E., & Montalescot, G.
- Affiliations
- Université de Montpellier (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Centre Hospitalier De Pau (FR)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Hôpital Cochin (FR)
- Hôpital Lariboisière (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Corresponding author
- Montalescot, Gilles
- ORCID
- Cayla, Guillaume
- Cuisset, Thomas
- Silvain, Johanne
- Leclercq, Florence
- Delarche, Nicolas
- Bellemain-Appaix, Anne
- Carrié, Didier
- Aubry, Pierre
- Sabouret, Pierre
- Beygui, Farzin
- Pouillot, Christophe
- Varenne, Olivier
- Henry, Patrick
- Motreff, Pascal
- Elhadad, Simon
- Salem, Joe-Elie
- Abtan, Jérémie
- Rousseau, Hélène
- Collet, Jean-Philippe
- Montalescot, Gilles
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 388
- Issue
- 10055
- Pages
- 2015-2022
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2509918966
- Cited by
- 380
- References
- 39
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 25 · 2023: 38 · 2022: 42 · 2021: 43 · 2020: 35 · 2019: 40 · 2018: 61 · 2017: 43 · 2016: 8
- FWCI
- 41.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- monitoring, antiplatelet therapy, prasugrel, elderly patients, acute coronary syndrome, coronary stenting, bleeding complications, stent thrombosis, major adverse cardiovascular events, individualised medicine, dual antiplatelet therapy, clopidogrel, ticagrelor, glycoprotein IIb/IIIa inhibitors, bleeding risk stratification, benefits and risks
- MeSH terms
- Prasugrel Hydrochloride, Aged, Aged, 80 and over, Drug Administration Schedule, Female, Humans, Male, Monitoring, Physiologic, Platelet Aggregation Inhibitors, Platelet Function Tests, Stents, Risk Assessment, Acute Coronary Syndrome, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(16)31323-x
- The paper
- Cayla, G., Cuisset, T., Silvain, J., Leclercq, F., Manzo-Silberman, S., Saint-Etienne, C., Delarche, N., Bellemain-Appaix, A., Range, G., El Mahmoud, R., Carrié, D., Belle, L., Souteyrand, G., Aubry, P., Sabouret, P., du Fretay, X. H., Beygui, F., Bonnet, J.-L., Lattuca, B., . . . Montalescot, G. (2016). Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(16)31323-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.